Impact of hydrocortisone replacement on bone mineral density and bone turnover markers in patients with primary adrenal insufficiency

Yazidi, Meriem; Danguir, Cyrine; Maamer, Dhouha; Oueslati, Ibtissem; Khiari, Karima; Elleuch, Mohamed; Feki, Moncef; Chihaoui, Melika

doi:10.2478/enr-2022-0022

Abstract

Objective. The study was aimed to assess the effect of hydrocortisone (HC) replacement therapy on bone mineral density (BMD) and bone turnover markers in patients with primary adrenal insufficiency (PAI).

Methods. A cross-sectional study was conducted in 37 PAI patients treated with HC. BMD and selected bone turnover markers (β-crosslaps and osteocalcin) were measured. A stepwise binary logistic regression model was applied to determine the independent variables associated with low BMD.

Results. Osteoporosis was noted in 14.3% and osteopenia in 34.3% of cases. These patients were older (p=0.01) and received higher daily HC dose compared to patients with normal BMD (p=0.01). BMD values in the lumbar spine and the femoral neck were negatively correlated with daily HC dose (r=–0.36, p=0.03 and r=–0.34, p=0.05, respectively). Plasma osteocalcin was negatively correlated with disease duration (r=–0.38, p=0.02) and cumulative HC dose (r=–0.43, p<0.01). In multivariate analysis, a daily HC dose ≥12 mg/m2/day was independently associated with a higher risk of osteopenia/osteoporosis [OR (95% CI), 9.0 (1.1–74.6); p=0.04].

Conclusions. Impaired bone mineralization in patients with PAI is correlated with HC dose. A daily HC dose ≥12 mg/m²/day was associated with an increased risk of osteopenia and osteoporosis in these patients.

References

Arlt W, Rosenthal C, Hahner S, Allolio B. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol 64, 384–389, 2006.10.1111/j.1365-2265.2006.02473.x16584509
Search in Google Scholar Back to article
Behan L, Kelleher G, Hannon MJ, Brady JJ, Rogers B, Tormey W, et al. Low dose hydrocortisone replacement therapy is associated with improved bone remodeling balance in hypopituitary male patients. Eur J Endocrinol 170, 141–150, 2013.10.1530/EJE-13-059624123094
Search in Google Scholar Back to article
Bensing S, Hulting AL, Husebye ES, Kampe O, Lovas K. Epidemiology, quality of life and complications of primary adrenal insufficiency: a review. Eur J Endocrinol 175, 107–116, 2016.10.1530/EJE-15-124227068688
Search in Google Scholar Back to article
Bentivegna G, Osella G, Pia A, Terzolo M. Effects on bone health of glucocorticoid replacement therapy in primary and secondary adrenal insufficiency: A review. Curr Opinion Endocr Metab Res 3, 31–37, 2018.10.1016/j.coemr.2018.02.008
Search in Google Scholar Back to article
Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 101, 364–389, 2016.10.1210/jc.2015-1710488011626760044
Search in Google Scholar Back to article
Braatvedt GD, Joyce M, Evans M, Clearwater J, Reid IR. Bone mineral density in patients with treated Addison’s disease. Osteoporos Int 10, 435–440, 1999.10.1007/s00198005025110663342
Search in Google Scholar Back to article
Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab 86, 1968–1972, 2001.10.1210/jcem.86.5.748311344193
Search in Google Scholar Back to article
Camozzi V, Betterle C, Frigo AC, Zaccariotto V, Zaninotto M, De Caneva E, Lucato P, Gomiero W, Garelli S, Sabbadin C, Salva M, Costa MD, Boscaro M, Luisetto G. Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine 59, 319–329, 2018.10.1007/s12020-017-1380-828795340
Search in Google Scholar Back to article
Chihaoui M, Yazidi M, Chaker F, Belouidhnine M, Kanoun F, Lamine F, Ftouhi B, Sahli H, Slimane H. Bone mineral density in Sheehan’s syndrome; prevalence of low bone mass and associated factors. J Clin Densitom 19, 413–418, 2016Chikada N, Imaki T, Hotta M, Sato K, Takano K. An assessment of bone mineral density in patients with Addison’s disease and isolated ACTH deficiency treated with glucocorticoid. Endocr J 51, 355–360, 2004.10.1016/j.jocd.2016.02.00226993664
Search in Google Scholar Back to article
Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 20, 843–851, 2009.10.1007/s00198-009-0838-919190842
Search in Google Scholar Back to article
Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J, Chatterjee VK. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metabol 93, 400–409, 2008.10.1210/jc.2007-1134
Search in Google Scholar Back to article
Holick MF. Vitamin D deficiency. N Engl J Med 357, 266–281, 2007.10.1056/NEJMra070553
Search in Google Scholar Back to article
Jodar E, Valdepenas MPR, Martinez G, Jara A, Hawkins F. Long-term follow-up of bone mineral density in Addison’s disease. Clin Endocrinol 58, 617–620, 2003.10.1046/j.1365-2265.2003.01761.x
Search in Google Scholar Back to article
Koetz KR, Ventz M, Diederich S, Quinkler M. Bone mineral density is not significantly reduced in adult patients on low dose glucocorticoid replacement therapy. J Clin Endocrinol Metabol 97, 85–92, 2012.10.1210/jc.2011-2036
Search in Google Scholar Back to article
Lovas K, Gjesdal CG, Christensen M, Wolff AB, Almas B, Svartberg J, Fougner KJ, Syversen U, Bollerslev J, Falch JA, Hunt PJ, Chatterjee VK, Husebye ES. Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur J Endocrinol 160, 993–1002, 2009.10.1530/EJE-08-0880
Search in Google Scholar Back to article
Meddeb N, Sahli H, Chahed M, Abdelmoula J, Feki M, Salah H, Frini S, Kaabachi N, Belkahia Ch, Mbazaa R, Zouari B, Sellami S. Vitamin D deficiency in Tunisia. Osteoporos Int 16, 180–183, 2005.10.1007/s00198-004-1658-6
Search in Google Scholar Back to article
Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, Weetman AP. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol 46, 255–261, 1997.10.1046/j.1365-2265.1997.780907.x
Search in Google Scholar Back to article
Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 843, 1–129, 1994.
Search in Google Scholar Back to article
Schulz J, Frey KR, Cooper MS, Zopf K, Ventz M, Diederich S, Quinkler M. Reduction in daily HC dosage improves bone health in primary adrenal insufficiency. Eur J Endocrinol (Oxf) 174, 531–538, 2016.10.1530/EJE-15-1096
Search in Google Scholar Back to article
Valero MA, Leon M, Ruiz Valdepenas MP, Larrodera L, Lopez MB, Papapietro K, Jara A, Hawkins F. Bone density and turnover in Addison’s disease: effect of glucocorticoid treatment. Bone Miner 26, 9–17, 1994.10.1016/S0169-6009(08)80158-4
Search in Google Scholar Back to article
Weinstein RS. Glucocorticoid-induced bone disease. N Engl J Med 365, 62–70, 2011.10.1056/NEJMcp101292621732837
Search in Google Scholar Back to article
Zelissen PMJ, Croughs R, Van Rijk P, Raymakers A. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120, 207, 1994.10.7326/0003-4819-120-3-199402010-000058273983
Search in Google Scholar Back to article

Impact of hydrocortisone replacement on bone mineral density and bone turnover markers in patients with primary adrenal insufficiency

Abstract

Paradigm

My account